|
1
|
Taphoorn MJB, Dirven L, Kanner AA,
Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen
TC, Sroubek J, et al: Influence of treatment with tumor-treating
fields on health-related quality of life of patients with newly
diagnosed glioblastoma: A secondary analysis of a randomized
clinical trial. JAMA Oncol. 4:495–504. 2018.
|
|
2
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017.
|
|
3
|
Pink RC and Carter DRF: Pseudogenes as
regulators of biological function. Essays Biochem. 54:103–112.
2013.
|
|
4
|
Lou W, Ding B and Fu P: Pseudogene-derived
lncRNAs and Their miRNA sponging mechanism in human cancer. Front
Cell Dev Biol. 8:852020.
|
|
5
|
Poliseno L, Salmena L, Zhang J, Carver B,
Haveman WJ and Pandolfi PP: A coding-independent function of gene
and pseudogene mRNAs regulates tumour biology. Nature.
465:1033–1038. 2010.
|
|
6
|
Chan JJ, Kwok ZH, Chew XH, Zhang B, Liu C,
Soong TW, Yang H and Tay Y: A FTH1 gene:Pseudogene:microRNA network
regulates tumorigenesis in prostate cancer. Nucleic Acids Res.
46:1998–2011. 2018.
|
|
7
|
Karreth FA, Reschke M, Ruocco A, Ng C,
Chapuy B, Léopold V, Sjoberg M, Keane TM, Verma A, Ala U, et al:
The BRAF pseudogene functions as a competitive endogenous RNA and
induces lymphoma in vivo. Cell. 161:319–332. 2015.
|
|
8
|
Zhou D, Ren K, Wang M, Wang J, Li E, Hou
C, Su Y, Jin Y, Zou Q, Zhou P and Liu X: Long non-coding RNA
RACGAP1P promotes breast cancer invasion and metastasis via
miR-345-5p/RACGAP1-mediated mitochondrial fission. Mol Oncol.
15:543–559. 2021.
|
|
9
|
Gao KM, Chen XC, Zhang JX, Wang Y, Yan W
and You YP: A pseudogene-signature in glioma predicts survival. J
Exp Clin Cancer Res. 34:232015.
|
|
10
|
Wang Y, Liu X, Guan G, Xiao Z, Zhao W and
Zhuang M: Identification of a five-pseudogene signature for
predicting survival and its ceRNA network in glioma. Front Oncol.
9:10592019.
|
|
11
|
Wang S, Qi Y, Gao X, Qiu W, Liu Q, Guo X,
Qian M, Chen Z, Zhang Z, Wang H, et al: Hypoxia-induced lncRNA
PDIA3P1 promotes mesenchymal transition via sponging of miR-124-3p
in glioma. Cell Death Dis. 11:1682020.
|
|
12
|
Liao K, Qian Z, Zhang S, Chen B, Li Z,
Huang R, Cheng L, Wang T, Yang R, Lan J, et al: The LGMN pseudogene
promotes tumor progression by acting as a miR-495-3p sponge in
glioblastoma. Cancer Lett. 490:111–123. 2020.
|
|
13
|
Du P, Liao Y, Zhao H, Zhang J, Muyiti
Keremu and Mu K: ANXA2P2/miR-9/LDHA axis regulates Warburg effect
and affects glioblastoma proliferation and apoptosis. Cell Signal.
74:1097182020.
|
|
14
|
Theng SS, Wang W, Mah WC, Chan C, Zhuo J,
Gao Y, Qin H, Lim L, Chong SS, Song J and Lee CG: Disruption of
FAT10-MAD2 binding inhibits tumor progression. Proc Natl Acad Sci
USA. 111:E5282–E5291. 2014.
|
|
15
|
Yuan R, Wang K, Hu J, Yan C, Li M, Yu X,
Liu X, Lei J, Guo W, Wu L, et al: Ubiquitin-like protein FAT10
promotes the invasion and metastasis of hepatocellular carcinoma by
modifying β-catenin degradation. Cancer Res. 74:5287–5300.
2014.
|
|
16
|
Ma C, Zhang Z, Cui Y, Yuan H and Wang F:
Silencing Fat10 inhibits metastasis of osteosarcoma. Int J Oncol.
49:666–674. 2016.
|
|
17
|
Zou Y, Ouyang Q, Wei W, Yang S, Zhang Y
and Yang W: FAT10 promotes the invasion and migration of breast
cancer cell through stabilization of ZEB2. Biochem Biophys Res
Commun. 506:563–570. 2018.
|
|
18
|
Xue F, Zhu L, Meng QW, Wang L, Chen XS,
Zhao YB, Xing Y, Wang XY and Cai L: FAT10 is associated with the
malignancy and drug resistance of non-small-cell lung cancer. Onco
Targets Ther. 9:4397–4409. 2016.
|
|
19
|
Yuan J, Tu Y, Mao X, He S, Wang L, Fu G,
Zong J and Zhang Y: Increased expression of FAT10 is correlated
with progression and prognosis of human glioma. Pathol Oncol Res.
18:833–839. 2012.
|
|
20
|
Dai B, Zhang Y, Zhang P, Pan C, Xu C, Wan
W, Wu Z, Zhang J and Zhang L: Upregulation of p-Smad2 contributes
to FAT10-induced oncogenic activities in glioma. Tumour Biol.
37:8621–8631. 2016.
|
|
21
|
Yan Y, Zhang L, Jiang Y, Xu T, Mei Q, Wang
H, Qin R, Zou Y, Hu G, Chen J and Lu Y: LncRNA and mRNA interaction
study based on transcriptome profiles reveals potential core genes
in the pathogenesis of human glioblastoma multiforme. J Cancer Res
Clin Oncol. 141:827–838. 2015.
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
23
|
Zhou J, Wang H, Hong F, Hu S, Su X, Chen J
and Chu J: CircularRNA circPARP4 promotes glioblastoma progression
through sponging miR-125a-5p and regulating FUT4. Am J Cancer Res.
11:138–156. 2021.
|
|
24
|
He H, Wang Y, Ye P, Yi D, Cheng Y, Tang H,
Zhu Z, Wang X and Jin S: Long noncoding RNA ZFPM2-AS1 acts as a
miRNA sponge and promotes cell invasion through regulation of
miR-139/GDF10 in hepatocellular carcinoma. J Exp Clin Cancer Res.
39:1592020.
|
|
25
|
Cui Y, Yi L, Zhao JZ and Jiang YG: Long
noncoding RNA HOXA11-AS functions as miRNA sponge to promote the
glioma tumorigenesis through targeting miR-140-5p. DNA Cell Biol.
36:822–828. 2017.
|
|
26
|
Zhang JY, Wang M, Tian L, Genovese G, Yan
P, Wilson JG, Thadhani R, Mottl AK, Appel GB, Bick AG, et al: UBD
modifies APOL1-induced kidney disease risk. Proc Natl Acad Sci USA.
115:3446–3451. 2018.
|
|
27
|
Aichem A and Groettrup M: The
ubiquitin-like modifier FAT10 in cancer development. Int J Biochem
Cell Biol. 79:451–461. 2016.
|
|
28
|
Liu X, Chen L, Ge J, Yan C, Huang Z, Hu J,
Wen C, Li M, Huang D, Qiu Y, et al: The ubiquitin-like protein
FAT10 stabilizes eEF1A1 expression to promote tumor proliferation
in a complex manner. Cancer Res. 76:4897–4907. 2016.
|
|
29
|
Wu D, Wang L, Yang Y, Huang J, Hu Y, Shu
Y, Zhang J and Zheng J: MAD2-p31comet axis deficiency
reduces cell proliferation, migration and sensitivity of
microtubule-interfering agents in glioma. Biochem Biophys Res
Commun. 498:157–163. 2018.
|
|
30
|
Scrideli CA, Carlotti CG Jr, Okamoto OK,
Andrade VS, Cortez MAA, Motta FJN, Lucio-Eterovic AK, Neder L,
Rosemberg S, Oba-Shinjo SM, et al: Gene expression profile analysis
of primary glioblastomas and non-neoplastic brain tissue:
Identification of potential target genes by oligonucleotide
microarray and real-time quantitative PCR. J Neurooncol.
88:281–291. 2008.
|
|
31
|
Biterge-Sut B: Alterations in eukaryotic
elongation factor complex proteins (EEF1s) in cancer and their
implications in epigenetic regulation. Life Sci.
238:1169772019.
|
|
32
|
Choi Y, Kim JK and Yoo JY: NFκB and STAT3
synergistically activate the expression of FAT10, a gene
counteracting the tumor suppressor p53. Mol Oncol. 8:642–655.
2014.
|
|
33
|
Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D
and Chen J: The challenges and the promise of molecular targeted
therapy in malignant gliomas. Neoplasia. 17:239–255. 2015.
|
|
34
|
Yan J, Lei J, Chen L, Deng H, Dong D, Jin
T, Liu X, Yuan R, Qiu Y, Ge J, et al: Human leukocyte antigen F
locus adjacent transcript 10 overexpression disturbs WISP1 protein
and mRNA expression to promote hepatocellular carcinoma
progression. Hepatology. 68:2268–2284. 2018.
|
|
35
|
Jing D, Zhang Q, Yu H, Zhao Y and Shen L:
Identification of WISP1 as a novel oncogene in glioblastoma. Int J
Oncol. 51:1261–1270. 2017.
|
|
36
|
Tao W, Chu C, Zhou W, Huang Z, Zhai K,
Fang X, Huang Q, Zhang A, Wang X, Yu X, et al: Dual role of WISP1
in maintaining glioma stem cells and tumor-supportive macrophages
in glioblastoma. Nat Commun. 11:30152020.
|
|
37
|
He L, Zhou H, Zeng Z, Yao H, Jiang W and
Qu H: Wnt/β-catenin signaling cascade: A promising target for
glioma therapy. J Cell Physiol. 234:2217–2228. 2019.
|
|
38
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016.
|
|
39
|
Chen X, Wan L, Wang W, Xi WJ, Yang AG and
Wang T: Re-recognition of pseudogenes: From molecular to clinical
applications. Theranostics. 10:1479–1499. 2020.
|
|
40
|
Johnsson P, Ackley A, Vidarsdottir L, Lui
WO, Corcoran M, Grandér D and Morris KV: A pseudogene
long-noncoding-RNA network regulates PTEN transcription and
translation in human cells. Nat Struct Mol Biol. 20:440–446.
2013.
|
|
41
|
Xu Y, Yu X, Wei C, Nie F, Huang M and Sun
M: Over-expression of oncigenic pesudogene DUXAP10 promotes cell
proliferation and invasion by regulating LATS1 and β-catenin in
gastric cancer. J Exp Clin Cancer Res. 37:132018.
|
|
42
|
Lee CGL, Ren J, Cheong ISY, Ban KHK, Ooi
LLPJ, Yong Tan S, Kan A, Nuchprayoon I, Jin R, Lee KH, et al:
Expression of the FAT10 gene is highly upregulated in
hepatocellular carcinoma and other gastrointestinal and
gynecological cancers. Oncogene. 22:2592–2603. 2003.
|
|
43
|
Lukasiak S, Schiller C, Oehlschlaeger P,
Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P,
Breuhahn K and Groettrup M: Proinflammatory cytokines cause FAT10
upregulation in cancers of liver and colon. Oncogene. 27:6068–6074.
2008.
|
|
44
|
Buerger S, Herrmann VL, Mundt S, Trautwein
N, Groettrup M and Basler M: The ubiquitin-like modifier FAT10 is
selectively expressed in medullary thymic epithelial cells and
modifies T cell selection. J Immunol. 195:4106–4116. 2015.
|
|
45
|
Canaan A, Yu X, Booth CJ, Lian J, Lazar I,
Gamfi SL, Castille K, Kohya N, Nakayama Y, Liu YC, et al:
FAT10/diubiquitin-like protein-deficient mice exhibit minimal
phenotypic differences. Mol Cell Biol. 26:5180–1589. 2006.
|
|
46
|
Basler M, Buerger S and Groettrup M: The
ubiquitin-like modifier FAT10 in antigen processing and
antimicrobial defense. Mol Immunol. 68:129–132. 2015.
|
|
47
|
Kandel-Kfir M, Garcia-Milan R, Gueta I,
Lubitz I, Ben-Zvi I, Shaish A, Shir L, Harats D, Mahajan M, Canaan
A and Kamari Y: IFNγ potentiates TNFα/TNFR1 signaling to induce
FAT10 expression in macrophages. Mol Immunol. 117:101–109.
2020.
|
